Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hypoxia × Gynecologic × Clear all

Phase

Phase NA 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6 Gastrointestinal 3 Head & Neck 2 CNS 2 Sarcoma 1 Gynecologic 1 Genitourinary 1 Breast 1

Conditions

Ovarian Neoplasms 719 Uterine Cervical Neoplasms 350 Endometrial Neoplasms 257 Fallopian Tube Neoplasms 254 Carcinoma, Ovarian Epithelial 226 Recurrence 76 Neoplasms 76 Breast Neoplasms 72 Peritoneal Neoplasms 58 Uterine Neoplasms 46 Colorectal Neoplasms 46 Vulvar Neoplasms 44 Uterine Cervical Dysplasia 44 Sarcoma 42 Carcinoma, Non-Small-Cell Lung 37 Neoplasm Metastasis 34 Stomach Neoplasms 33 Pancreatic Neoplasms 31 Testicular Neoplasms 27 Melanoma 27 Vaginal Neoplasms 26 Prostatic Neoplasms 24 Papillomavirus Infections 23 Lung Neoplasms 23 Carcinoma 21 Esophageal Neoplasms 20 Squamous Intraepithelial Lesions 19 Head and Neck Neoplasms 19 Urinary Bladder Neoplasms 18 Squamous Cell Carcinoma of Head and Neck 17

Interventions

Magnetic Resonance Spectroscopy 1 Injections 1 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02233387 2019-03-08

HX4-cervix

Maastricht Radiation Oncology

Phase 2 Terminated

Hypoxia, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡